Prevention or mitigation of T-cell engaging agent-related adverse effects

A method for preventing or mitigating an adverse effect related to the administration of a T cell bispecific antibody to an individual, comprising administering (a) a T cell bispecific antibody and (b) an inhibitor that inhibits mTOR signaling to the individual, wherein the adverse effect is prevented or mitigated, wherein the T cell bispecific antibody binds to CD3 and a target cell antigen, and wherein the method does not comprise administering a CAR-T cell, and wherein administering the inhibitor that inhibits mTOR signaling causes inhibition of an adverse effect related to administering the T cell bispecific antibody.